Salvinorin a produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel

Anesthesiology

Volumn 114, Issue 2, 2011, Pages 374-379

  Su, Diansan ^a   Riley, John ^b   Kiessling, Willis J ^b   Armstead, William M ^b   Liu, Renyu ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 NITROINDAZOLE; ADENOSINE TRIPHOSPHATE; CYCLIC GMP; ENDOTHELIN; GLIBENCLAMIDE; IBERIOTOXIN; KAPPA OPIATE RECEPTOR; N(G) NITROARGININE; NALOXONE; NITRIC OXIDE SYNTHASE; NORBINALTORPHIMINE; POTASSIUM CHANNEL; SALVINORIN A; SULPIRIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTERY DIAMETER; ARTICLE; BRAIN ARTERY; CEREBROSPINAL FLUID; HYPOCAPNIA; NONHUMAN; PIGLET; PRIORITY JOURNAL; VASODILATATION;

EID: 79251638019     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318204e029     Document Type: Article

References (26)

1. Vortherms TA, Roth BL: Salvinorin A: From natural product to human therapeutics. Mol Interv 2006; 6:257-65
2. Yan F, Roth BL: Salvinorin A: A novel and highly selective kappa-opioid receptor agonist. Life Sci 2004; 75:2615-9
3. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB: Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002; 99:11934-9
4. Walsh SL, Strain EC, Abreu ME, Bigelow GE: Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001; 157:151-62
5. Rimoy GH, Wright DM, Bhaskar NK, Rubin PC: The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist Eur J Clin Pharmacol 1994; 46:203-7
6. Braida D, Capurro V, Zani A, Rubino T, Viganò D, Parolaro D, Sala M: Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol 2009; 157:844-53
7. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS: Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008; 41:1044-50
8. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, Eddington ND: Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 2009; 72:471-7
9. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H: In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 2009; 39:391-8
10. Nemeth CL, Paine TA, Rittiner JE, Béguin C, Carroll FI, Roth BL, Cohen BM, Carlezon WA Jr: Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) 2010; 210:263-74
11. Grilli M, Neri E, Zappettini S, Massa F, Bisio A, Romussi G, Marchi M, Pittaluga A: Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals. Neuropharmacology 2009; 57:523-30
12. Devine JO, Armstead WM: The role of nitric oxide in opioidinduced pial artery vasodilation. Brain Res 1995; 675:257-63
13. Pei JM, Chen M, Wang YM, Wen J, Zhu YL: Kappa-opioid receptor stimulation contributes to aortic artery dilation through activation of K(ATP) channel in the rats. Sheng Li Xue Bao 2003; 55:91-5
14. Beers R, Camporesi E: Remifentanil update: Clinical science and utility. CNS Drugs 2004; 18:1085-104
15. Goyagi T, Toung TJ, Kirsch JR, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A: Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats. Stroke 2003; 34:1533-8
16. Zeynalov E, Nemoto M, Hurn PD, Koehler RC, Bhardwaj A: Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. J Cereb Blood Flow Metab 2006; 26:414-20
17. Ko EA, Han J, Jung ID, Park WS: Physiological roles of K- channels in vascular smooth muscle cells. J Smooth Muscle Res 2008; 44:65-81
18. Akrouh A, Halcomb SE, Nichols CG, Sala-Rabanal M: Molecular biology of K(ATP) channels and implications for health and disease. IUBMB Life 2009; 61:971-8
19. Xie J, Duan L, Qian X, Huang X, Ding J, Hu G: K(ATP) channel openers protect mesencephalic neurons against MPP-induced cytotoxicity via inhibition of ROS production. J Neurosci Res 2010; 88:428-37
20. Zhu HL, Luo WQ, Wang H: Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels. Neuroscience 2008; 157:884-94
21. Sun XL, Hu G: ATP-sensitive potassium channels: A promising target for protecting neurovascular unit function in stroke. Clin Exp Pharmacol Physiol 2010; 37:243-52
22. Sun HS, Feng ZP, Barber PA, Buchan AM, French RJ: Kir6.2- containing ATP-sensitive potassium channels protect cortical neurons from ischemic/anoxic injury in vitro and in vivo. Neuroscience 2007; 144:1509-15
23. Seeman P, Guan HC, Hirbec H: Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009; 63:698-704
24. Rabinstein AA, Lanzino G, Wijdicks EF: Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 2010; 9:504-19
25. Duhaime AC: Large animal models of traumatic injury to the immature brain. Dev Neurosci 2006; 28:380-7
26. Tanaka Y, Imai H, Konno K, Miyagishima T, Kubota C, Puentes S, Aoki T, Hata H, Takata K, Yoshimoto Y, Saito N: Experimental model of lacunar infarction in the gyrencephalic brain of the miniature pig: Neurological assessment and histological, immunohistochemical, and physiological evaluation of dynamic corticospinal tract deformation. Stroke 2008; 39:205-12